A meta-analysis of 16 randomized controlled trials with 1,641 patients assessed the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) for treating and preventing peritoneal carcinomatosis in advanced gastric cancer. Surgery plus HIPEC improved overall survival in both prophylactic (HR 0.56) and therapeutic (HR 0.57) settings, with a 3-year mortality rate of 32% for the prophylactic HIPEC group versus 55% for controls. Recurrence rates were reduced without significant differences in morbidity. HIPEC shows potential for treating and preventing peritoneal carcinomatosis, though more large-scale studies are needed for a definitive recommendation.
Review by Stefano M, Perrina D (…) Catena F et 13 al. in J Gastrointest Surg
Copyright © 2024 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights reserved.